Fluofarma signed a multiyear collaboration agreement with Roche focused on developing new tools for predicting the hepatotoxicity of early-stage drug candidates. The companies aim to develop miniaturized cell-based assays using high-throughput flow cytrometry along with computational models for predicting hepatotoxicity and safety profiling of compounds in liver cells.

Fluofarma platforms include automated confocal microscopy, automated flow cytometry, as well as laser scanning cytometry and combine cell-based assays with large-scale analysis. The company claims its  technologies enable the simultaneous functional analysis of several molecular events in single cells.